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ABSTRACT
Recently, various long non-coding RNAs (lncRNAs) have been reported to have 
significant therapeutic or prognostic value. However, the expression of lncRNAs has 
not been investigated in T and NK cell lymphoma. Thus, we evaluated the biological 
and prognostic role of lncRNAs related to the polycomb repressive complex (PRC) 
and PRC markers in tissue samples and cell lines of T and NK cell lymphoma. Among 
the tested lncRNAs, MALAT1 was most highly expressed in clinical samples and cell 
lines. High expression of MALAT1 as well as BMI1 was related to poor prognosis in 
patients with mature T cell lymphoma. In the tissue samples, BMI1 expression showed 
a positive correlation with EZH2, SUZ12, H3K27me3, and MALAT1. Multiple linear 
regression analysis showed that BMI1 expression was independently associated with 
H3K27me3. Direct binding of MALAT1 to the PRC2 components (EZH2 and SUZ12) 
was observed in a T cell lymphoma cell line; however, no direct binding of MALAT1 
with H3K27me3 and BMI1 (a PRC1 component) was observed.
In T and NK cell lymphomas, MALAT1 was related to poor prognosis. MALAT1 directly 
binds to EZH2 and SUZ12, and BMI1 activation may be induced possibly through H3K27me3.
INTRODUCTION
The incidence of T and natural killer (NK) cell lymphoma 
is particularly high in the East Asian population; however, 
therapeutic options are currently limited to conventional 
chemotherapy and radiotherapy with no available target agents 
[1]. Long non-coding RNAs (lncRNAs) are non-protein-coding 
RNA molecules longer than 200 nucleotides that regulate 
gene expression in chromosome remodeling, transcription, 
and post-transcriptional processes [2]. Recently, the aberrant 
expression of lncRNAs has been investigated in many human 
diseases, including various malignant tumors [2–7]. LncRNAs 
are deregulated in a number of cancers, demonstrating both 
oncogenic and tumor-suppressive roles, thus suggesting that 
their aberrant expression may be a substantial contributor 
to cancer development. Moreover, many studies have 
demonstrated the clinicopathologic significance of lncRNAs 
in terms of associations with prognosis or a therapeutic 
benefit, suggesting possible therapeutic targets or candidate 
biomarkers[8–10]. With respect to hematologic malignancies, 
the role of lncRNAs has been studied in B cell lymphoma/
leukemia [11–15], but not in T and NK cell lymphoma.
Some lncRNAs are known to play roles in the regulation 
of gene expression via a mechanism involving interaction 
with the polycomb repressive complex (PRC) pathway 
[16]. The PRC proteins consist of two main families, PRC1 
(including BMI1) and PRC2 (including EZH2, SUZ12, and 
EED1) [17]. In general, PRC2 is related to the trimethylation 
of histone H3 at lysine 27 (H3K27me3), whereas PRC1 
interacts in the genome regions via H3K27me3 [18].
Association of lncRNAs and PRC-related markers 
has been reported in different types of malignant tumors 
[19–23]. For example, increased expression of the lncRNA 
metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1) in renal cell carcinoma was reported to promote 
aggressive biological behavior through interactions with 
EZH2 [24]. In our previous study, a high frequency of 
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patients with T and NK cell lymphomas showed activation 
of PRC pathway-related markers (EZH2, SUZ12, 
H3K27me3, and BMI1), and high expression of BMI1 
was related to poor prognosis. These results implied that 
activation of the PRC pathway, especially BMI1 activation, 
which is induced by PRC2-H3K27me3 activation, may be 
related to the clinically aggressive behaviors of T and NK 
cell lymphomas [25]. However, the regulation of lncRNAs 
and the PRC pathway as well as the prognostic role of 
lncRNAs in T and NK cell lymphomas remain unclear.
Therefore, in the present study, we investigated the 
expression of lncRNAs in T and NK cell lymphomas and 
analyzed the relationships between these lncRNAs and the 
PRC pathway as well as their prognostic implications.
RESULTS
Expression of PRC markers determined by 
immunohistochemistry in T and NK cell 
lymphoma tissue
As shown in Figure 1, many lymphoma cases 
showed high expression of EZH2, SUZ12, H3K27me3, 
and BMI1 in the tumor nuclei. The frequencies of 
cases showing high expression, which was defined 
as positive expression in>75% of tumor cells, were 
55.2% (91/167) for EZH2, 32.3% (54/167) for SUZ12, 
37.1% (62/167) for H3K27me3, and 31.1% (52/167) 
for BMI1.
Figure 1: Representative immunohistochemical stains in T cell lymphoma samples (400×). (A) EZH2, (B) SUZ12, 
(C) H3K27me3, and (D) BMI1 Lymphoma cells showed strong nuclear expression of each marker.
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Expression of lncRNAs in T and NK cell 
lymphoma tissues and cell lines
Among the seven types of lncRNAs tested, 
HOTAIR, MALAT1, KCNQ1, TUG1, H19, ANRIL, and 
HEIH, in the clinical samples of patients with T and NK 
cell lymphomas, MALAT1 showed distinctively high 
expression when compared to the others, followed by 
HOTAIR. The expression of the other lncRNAs, KCNQ1, 
TUG1, H19, ANRIL, and HEIH, was much lower or quite 
subtle (Figure 2A and Supplementary Table 1).
MALAT1 also showed distinctively high expression 
when compared to the other lncRNAs tested in cell lines 
derived from patients with various types of T and NK cell 
lymphomas and a cell line derived from a patient with 
diffuse large B-cell lymphoma (Figure 2B).
MALAT1 expression and PRC activation in T 
and NK cell lymphoma tissues
The expression levels of MALAT1 and the 
PRC-related markers EZH2, SUZ12, H3K27me3, and 
BMI1 showed positive correlations with each other. In 
particular, MALAT1 expression was positively correlated 
with BMI1 but not with EZH2, SUZ12, or H3K27me3, 
whereas BMI1 was positively correlated with all other 
markers (Figure 3 and Supplementary Figure 1). In 
multiple linear regression analysis, H3K27me3 was 
independently associated with BMI1 expression, and 
MALAT1 also revealed a tendency to be associated with 
BMI1 expression (Table 1).
Associations of MALAT1 expression and PRC 
activation with patient clinical characteristics
No significant difference in MALAT1 expression 
was noted among patients classified into the different 
subtypes of T and NK lymphomas: extranodal NK/T cell 
lymphoma of nasal type (ENKTL); mature (peripheral) T cell 
lymphoma(PTCL), including PTCL-not otherwise specified 
(NOS), angioimmunoblastic T cell lymphoma (AITL), and 
anaplastic large cell lymphoma (ALCL); and precursor T 
lymphoblastic lymphoma/leukemia (T-LBL) (Supplementary 
Figure 2). In addition, no distinct association was noted 
between MALAT1 expression and clinical factors such as 
age, pretreatment lactate dehydrogenase level, Ann-Arbor 
stage, International Prognostic Index score, anatomical sites 
of the tumor, or bone marrow involvement (Table 2).
However, high MALAT1 expression tended to be 
related to lower overall survival (Figure 4A). In particular, 
high MALAT1 expression was significantly related to a 
lower overall survival rate in cases of mature PTCL and 
T-LBL (Figure 3B and 3C). However, no such relationship 
between MALAT1 expression and overall survival was 
noted for patients with ENKTL (Figure 3D).
Similar to our previous study [25], high 
BMI1expression was significantly associated with lower 
overall survival in the mature T cell lymphoma group 
(P<0.001) as well as among all T and NK cell lymphoma 
cases (P<0.001). No significant association between BMI1 
and overall survival rate was observed in cases of T-LBL 
(P=0.237), and marginal significance was noted (P=0.053) 
in cases of ENKTL (Supplementary Figure 3).
Figure 2: Quantitative expression analysis of seven long non-coding RNAs (lncRNAs) mRNA normalized to GAPDH 
expression in (A) clinical samples of patients with T and NK cell lymphomas and (B) six cell lines. (A) MALAT1 showed 
distinctively higher expression when compared to the other types of lncRNAs in clinical samples of T and NK cell lymphomas. (B) MALAT1 
showed distinctively higher expression when compared to other types of lncRNAs in cell lines derived from various types of T and NK cell 
lymphomas and a cell line derived from a patient with diffuse large B-cell lymphoma (Toledo).
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Correlation between MALAT1 and PRC-related 
markers in the HH cell line
In the non-treated cell line derived from a patient 
with T cell lymphoma (HH cells), baseline protein 
expression levels of PRC-related markers, especially 
EZH2, SUZ12, BMI1, and H3K27me3, were very 
strong (Figure 5). To investigate the potential binding 
of MALAT1 with these PRC-related markers, an RNA 
immunoprecipitation study was performed. In the non-
treated HH cell lines, MALAT1 was significantly more 
enriched with the antibodies of EZH2, SUZ12, and 
H3K27me3 when compared to the control antibody IgG. 
However, no significant binding of MALAT1 with the 
BMI1 antibody was observed (Figure 6).
Changes of PRC-related markers following 
MALAT1 inhibition in the HH cell line
We confirmed that the transfected oligomers 
of the small interfering RNAs (si-RNAs) specific 
to MALAT1 (si-MALAT1), especiallysi-MALT1-a, 
efficiently inhibited MALAT1 expression (Figure 7A). 
At 48h after transfection, expression of the PRC-related 
markers EZH2, SUZ12, H3K27me3, and BMI1 was not 
significantly decreased according to the results of western 
blot analysis (Figure 7B).
In RNA immunoprecipitation, the fold enrichment 
level of MALAT1 bound to the control (IgG) did not 
change, even after knockdown of MALAT1. This result 
excluded the possibility of the non-specific binding of 
MALAT1 to the negative control or other non-target 
proteins. The fold enrichment levels of MALAT1 
bound to EZH2 and SUZ12significantly decreased after 
transfection of si-MALAT1 when compared to those of 
cells transfected with scramble siRNA. However, the fold 
enrichment levels of MALAT1 bound to H3K27me3 and 
BMI1 were not significantly changed, even after MALAT1 
inhibition. The fold enrichment levels of MALAT1 bound 
to EZH2, SUZ12, and H3K27me3 were similar (Figure 8).
DISCUSSION
Our study shows that MALAT1 expression is 
increased more substantially than the other lncRNAs 
evaluated in T and NK cell lymphomas. The MALAT1 
Figure 3: Correlation analysis between BMI1 protein expression and EZH2, SUZ12, H3K27me3, and MALAT1 in 
clinical samples of T and NK cell lymphomas. The expressions of BMI1, EZH2, SUZ12 and H3K27me3 evaluated protein by 
immunohistochemistry. MALAT1 expression measured using real-time RT-PCR. Correlation between BMI1 protein expression and EZH2, 
SUZ12 and H3K27me3, and MALAT1 mRNA was examined with two-sided Spearman coefficient. MALAT1 was positively correlated 
with BMI1 but not with EZH2, SUZ12, or H3K27me3, whereas BMI1 was positively correlated with EZH2, SUZ12, or H3K27me3.
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Table 2: Correlation between MALAT1 expression and clinicopathologic variables
Low MALAT1 
expression (%)
High MALAT1 
expression (%)
P value
Subtype 0.872
  ENKTL 11(52.4) 10(47.6)
  PTCL, NOS 15(60.0) 10(40.0)
AITL 7(53.8) 6(46.2)
  ALCL 16(66.7) 8(33.8)
  T-LBL 7(53.8) 6(46.2)
Sex 0.250
  Male 31(62.0) 19(38.0)
  Female 14(48.3) 15(51.7)
Age (years) 1.000
  <60 30(56.6) 23(43.4)
  ≥60 15(57.7) 11(42.3)
Primary site of tumor 0.394
  Head and neck 7(53.8) 6(46.2)
  Lymph node 27(55.1) 22(44.9)
  Gastrointestinal tract 5(71.4) 2(28.6)
  Soft tissue and bone 5(83.3) 1(16.7)
  Others (solid organs) 1(25.0) 3(75.0)
Ann Arbor stage 0.219
  Stage I & II 11(78.6) 3(21.4)
  Stage III&IV 27(58.7) 19(41.3)
LDH level 1.000
  Normal 12(66.7) 6(33.3)
  Elevated 25(69.4) 11(30.6)
Bone marrow involvement 0.397
  Absent 28(63.6) 16(36.4)
  Present 9(50.0) 9(50.0)
IPI score 0.165
  0-2 26(72.2) 10(27.8)
  3-5 12(52.2) 11(47.8)
Abbreviations: LDH, lactate dehydrogenase; IPI, International Prognostic Index; ENKTL, extranodal natural killer/T-cell 
lymphoma; PTCL-NOS, peripheral T cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T cell lymphoma; 
T-LBL, T lymphoblastic leukemia/lymphoma.
Information was not available in some cases; the actual number of cases (percentage) is presented in the parentheses.
Table 1: Multiple linear regression analysis of markers influencing BMI1 expression in clinical samples of patients 
with T and NK cell lymphoma
ß (95% CI) t P value
EZH2 0.012 (-018 to 0.21) 0.136 0.892
SUZ12 0.155 (-0.02 to 0.34) 1.816 0.072
H3K27me3 0.383 (0.21 to 0.56) 4.332 <0.001
MALAT1 0.165 (-0.02 to1.07) 1.913 0.058
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locus at 11q13.1 has been identified to harbor 
chromosomal translocation break points associated with 
cancer [2, 7, 26]. MALAT1 is also known as nuclear-
enriched abundant transcript2 (NEAT2), and was first 
identified as a novel non-coding RNA in non-small 
cell lung cancer [27]. Recently, the role of MALAT1 in 
tumor development has been extensively reported [19, 
21, 24, 26, 28–33]. MALAT1 was observed to promote 
malignancy in osteosarcoma, as its knockdown inhibited 
cell proliferation and invasion, and suppressed metastasis 
[34–36]. Silencing of MALAT1 expression reduced cell 
proliferation and invasion and increased apoptosis in 
renal cell carcinoma cells [24]. In addition, recent reports 
have indicated that MALAT1 expression is significantly 
associated with poor prognosis in various malignant 
tumors [28, 29, 31, 37, 38]. The results of the present 
study also demonstrated a worse prognosis for T and 
NK lymphoma patients in the high MALAT1 expression 
group, especially for those in the mature PTCL group, 
including PTCL-NOS, AITL and ALCL.
A recent study showed that the MALAT1 expression 
level was upregulated and promoted the activity of the 
PRC2 complex by interacting with the SUZ12 protein in 
bladder cancer [39]. In chemotherapy-resistant prostate 
cancer, MALAT1 was shown to directly interact with 
EZH2 protein, suggesting that MALAT1 may play 
a key role as an RNA cofactor of EZH2 and that the 
EZH2-MALAT1 association may be a new therapeutic 
target [21].
In our previous study, frequent activation of PRC 
pathway-related markers (EZH2, SUZ12, H3K27me3, 
and BMI1) was observed in patients with T and NK cell 
lymphomas, and the expression levels of these marker 
were closely correlated. Moreover, high expression of 
BMI1 was related to the poor prognosis of T and NK cell 
lymphoma patients. Therefore, the results of this previous 
study implied that activation of the PRC pathway, 
especially BMI1 activation, which is induced by PRC2-
H3K27me3 activation, may be related to the clinically 
aggressive behaviors of T and NK cell lymphomas [25].
Figure 4: Overall survival analysis according to MALAT1 expression in T and NK cell lymphomas using Kaplan-
Meier curves. (A) Overall T and NK cell lymphoma cases. (B) Mature (peripheral) T cell lymphoma. (C) Precursor T lymphoblastic 
lymphoma/leukemia (T-LBL). (D) Extranodal NK/T cell lymphoma of nasal type (ENKTL). High MALAT1 expression showed a tendency 
to be related to lower overall survival in all T and NK cell lymphoma cases (A). In the cases of mature (peripheral) T cell lymphoma, high 
MALAT1 expression was significantly related to a lower overall survival rate (B), and cases of T-LBL showed a similar tendency (C). For 
ENKTL, no distinct finding between MALAT1 expression and overall survival was noted (D).
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Figure 5: Western blot analysis of EZH2, SUZ12, H3K27me3, and BMI-1 in the HH cell line. All PRC pathway markers 
showed strong baseline expression in the non-treated HH cell line.
Figure 6: RNA immunoprecipitation assay in the non-treated HH cell line. MALAT1 directly binds with EZH2, SUZ12, and 
H3K27me3 but not with BMI1. IgG antibody was used as the control.
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Figure 7: Changes of interaction with PRC-related markers according to MALAT1 inhibition. (A) Transfected oligomers 
of si-MALAT1, especially, si-MALT1-a, efficiently inhibited MALAT1 expression in the HH cell line. (B) Western blot analysis of four 
PRC pathway markers after 48h transfection of si-MALAT1 in the HH cell line. After 48h of transfection, the expression of PRC-related 
markers, EZH2, SUZ12, H3K27me3, and BMI1 were not significantly decreased.
Figure 8: RNA immunoprecipitation of four PRC pathway markers after MALAT1 knockdown in HH cell lines. 
Interactions of MALAT1 with antibodies to EZH2 and SUZ12 significantly decreased after transfection of si-MALAT1 when compared 
to those observed after transfection of scramble siRNA. Interactions of MALAT1 with the antibody of H3K27me3 and BMI1 did not 
significantly change even after MALAT1 inhibition.
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In the present study, MALAT1, as well as the 
PRC-related markersEZH2, SUZ12, H3K27me3, and 
BMI1, were found to be positively correlated. Notably, 
H3K27me3 was identified as an independent factor related 
to BMI1 activation. To assess the direct binding between 
MALAT1 and PRC-related pathway markers, an RNA 
immunoprecipitation study was performed using the T 
cell lymphoma cell line, which shows high endogenous 
expression of PRC-related markers; this assay confirmed 
the direct binding of MALAT1 to EZH2, SUZ12, and 
H3K27me3. The bound MALAT1 level decreased in the 
following order: EZH2>SUZ12> H3K27me3; however, 
MALAT1 did not directly bind to BMI1. To exclude the 
possibility that the binding of MALAT1 to PRC-related 
markers may be an HH cell line-specific phenomenon, the 
MALAT1expression level was modified using an siRNA 
transfection method. When MALAT1 expression was 
knocked down, the level of binding of MALAT1 to EZH2 
and SUZ12 significantly decreased, whereas the binding to 
H3K27me3 or BMI1 was not affected.
Collectively, these observations suggest a molecular 
mechanism contributing to the development of T cell 
lymphomas. During the sequential processes of PRC 
pathway activation and chromatin remodeling in T cell 
lymphomas, MALAT1 may directly and specifically bind 
to PRC pathway proteins, particularly EZH2 and SUZ12, 
members of the PRC2 family, which may in turn induce 
H3K27me3. The low level of binding of H3K27me3 
to MALAT1 may be an indirect result of the sequential 
histone methylation through PRC recruitment. Because the 
protein expression of EZH2 or SUZ12 was not changed, 
even after the MALAT1 expression level was decreased 
by siRNA transfection, the low or baseline level of 
MALAT1 bound to H3K27me3 seemed to be unchanged 
due to the intact action of EZH2 and SUZ12. In fact, the 
fold enrichment level was similar for MALAT1 bound 
to EZH2, SUZ12, and H3K27me3 after knockdown 
of MALAT1. BMI1, a member of the PRC1 family, 
may be specifically and directly induced in response to 
H3K27me3; therefore, the correlation of BMI1 expression 
with the expression of PRC2 markers and MALAT1 could 
be an indirect consequence of the sequential processes of 
PRC pathway activation and chromatin remodeling in T 
cell lymphoma, without direct binding between BMI1 and 
MALAT1.
The direct binding of MALAT1 to the PRC2 
proteins EZH2, H3K27me3, and SUZ12 has been reported 
previously [21, 24, 39]. The present study confirmed the 
direct binding between MALAT1 and the PRC2 subunits 
EZH2 and SUZ12 in T cell lineage lymphoma. However, 
direct activation between MALAT1 and BMI1, a subunit 
of PRC1, was not identified in T cell lineage lymphoma. 
Nevertheless, our results suggest that MALAT1 may be 
an important molecule for sustaining PRC2-induced 
H3K27me3, leading to the subsequent BMI1 activation in 
T and NK cell lymphomas (Figure 9). The poor prognosis 
of T cell lymphoma patients with high BMI1 expression 
suggest that activated BMI1 might be involved in the 
progression to a high-risk phenotype.
In the present study, MALAT1 knockdown did 
not suppress the protein expression of EZH2, SUZ12, 
BMI1, and H3K27me3 in the in vitro analysis. Because 
the endogenous expression level of these molecules 
was very high, the 48-h transfection time using siRNA 
Figure 9: Hypothetical mechanism of the interaction of MALAT1 and the PRC repressive pathway. MALAT1 may 
directly and specifically bind to EZH2 and SUZ12. H3K27me3 may occur sequentially through EZH2 and SUZ12 recruitment by MALAT1, 
which may in turn induce BMI1 activation. Therefore, although H3K27me3 and BMI1 do not bind directly to MALAT1, their activation is 
induced by MALAT1 via recruitment of EZH2 and SUZ12.
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oligonucleotides might not have been sufficient to 
decrease the levels of these molecules, although the 
functional interaction of MALAT1 and PRC-related 
proteins was affected during this period. Alternatively, 
the short duration of the observation period and the lack 
of quantitative changes of PRC pathway markers might 
have contributed to the lack of an effect of MALAT1 
knockdown on cell survival in the present study. Further 
studies with longer observation times should be conducted 
using a small hairpin RNA transfection method or a 
vector-based system.
In summary, the expression of MALAT1 was 
increased in T and NK cell lymphoma, and high MALAT1 
expression was associated with inferior overall survival, 
especially for patients with mature T cell lymphoma 
subtypes. Direct binding of MALAT1 with EZH2 and 
SUZ12 was verified through RNA immunoprecipitation 
analysis, and further results suggested that overexpressed 
MALAT1 may induce BMI1 activation, which is itself 
related to poor patient prognosis. Collectively, these 
findings demonstrate that MALAT1 could serve as a 
prognostic marker as well as a therapeutic target in T and 
NK cell lymphomas.
MATERIALS AND METHODS
Patients and tissue samples
A total of 167 clinical samples obtained from 
patients with T and NK cell lymphomas diagnosed at the 
Department of Pathology at Severance Hospital from 
1999 to 2013 were included in this study. The inclusion 
criteria were as follows: 1) available paraffin blocks, 2) 
confirmed diagnosis by two pathologists (S.H.K and S.O.Y) 
according to current World Health Organization criteria [1]. 
Overall, 56 patients were diagnosed with ENKTL, 44 with 
PTCL-NOS, 16 with AITL, 32 with ALCL (16 anaplastic 
lymphoma kinase [ALK]-positive and 16 ALK-negative), 
and 19 with T-LBL. Clinical information was obtained 
from medical record review, and survival analysis was 
performed for 135 patients with available clinical data. The 
clinicopathologic characteristics of patients are summarized 
in Supplementary Table 2. This study was approved by the 
Institutional Review Board of Severance Hospital.
Cell lines and reagents
The following cell lines derived from patients with 
T or NK cell lymphomas and B cell lymphoma were used 
in the present study: YT, an Epstein-Barr virus (EBV)-
positive human NK-like leukemic cell line; SNK6, 
derived from an EBV-positive patient with NK/T cell 
lymphoma; Jurkat, a T lymphoblastic leukemia cell line; 
HH, a cell line derived from a patient with cutaneous T 
cell lymphoma; and MAC1, a cell line derived from a 
patient with ALK-negative ALCL were used in the study. 
All the cell lines derived from T or NK cell lymphomas 
were kindly provided by Prof. Jeon YK (Seoul National 
University College of Medicine, Seoul, Korea). The 
Toledo cell line, established from a patient with diffuse 
large B-cell lymphoma, purchased from American 
Type Culture Collection, was also used in this study 
for comparison. The reagents used for cell culture are 
summarized in Supplementary Table 4.
Tissue microarray construction
Tissue microarray blocks were prepared as 
described previously [40]. The hematoxylin–eosin slides 
were reviewed and representative formalin-fixed paraffin-
embedded (FFPE) archival blocks were selected for each 
case. Each block contained non-neoplastic tonsil tissue. 
Selected core tissue (3 mm in diameter) was obtained from 
the individual FFPE blocks (donor blocks) and arranged in 
recipient paraffin blocks (tissue microarray blocks) using 
a trephine apparatus. All tissue microarray blocks were 
confirmed to contain proper lymphoma lesions and non-
neoplastic tonsils after hematoxylin and eosin staining.
Immunohistochemistry and assessment
Immunohistochemistry for EZH2, SUZ12, BMI1, 
and H3K27me3 was performed on the tissue microarray 
blocks following a standard protocol, using a Ventana 
automatic immunostainer (Ventana, Benchmark, Tuscan, 
AZ). The primary antibodies used in this study and the 
specific immunohistochemistry conditions are listed in 
Supplementary Table 7. After deparaffinization, heat-
induced antigen retrieval was performed using citrate 
buffer (CC1 protocol; Ventana) of pH 6.0. Reactivity was 
visualized using the Ultra-View detection kit (Ventana). 
The positive rate for each marker was scored independently 
by two pathologists (S.H.K and S.O.Y). EZH2, SUZ12, 
BMI1, and H3K27me3 all showed nuclear expression. The 
percentage and intensity of positive-stained tumor cells 
were recorded by manually counting at least 500 tumor cells 
from representative fields in each case. The cut-off value 
for high expression of EZH2, SUZ12, H3K27me3, and 
BMI1 was 75% of tumor cells showing moderate to strong 
intensity as described in our previous study [25].
Analysis for lncRNA expression in clinical 
samples
FFPE tissue sections were prepared and stained with 
hematoxylin and eosin, and then the tumor areas were 
confirmed and marked under the microscope. The marked 
FFPE areas were dissected at a 10-mm thickness using a 
microtome. In general, four slices of a tissue section per case 
were used for RNA extraction. Total RNA was isolated using 
an RNeasyFFPEKit (Qiagen, Hilden, Germany) according to 
the manufacturer instructions. Extracts of RNA were verified 
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by measuring the ratios of A260/A280 and A260/A230 with 
an ND-1000 NanoDropspectrophotometer (NanoDrop, 
Wilmington, DE, USA). One step of reverse transcription 
and real-time PCR was performed using a Onestep SYBR 
PrimeScript RT-PCR kit (Takara, Japan). Primers for 
amplification of seven lncRNAs, HOTAIR, MALAT1, 
KCNQ1, TUG1, H19, ANRIL, and HEIH, and the reference 
gene GAPDH are summarized in Supplementary Table 3, 
which were designed using the Primer3-web interface (http://
frodo.wi.mit.edu/primer3/input.htm). Amplification was 
performed using an ABI StepOnePlus™ system (Applied 
Biosystems, Foster City, CA, USA). Relative lncRNA 
expression levels were normalized to the GAPDH expression 
level by the comparative cycle threshold (Ct) method (2-
ΔΔCt). The experiment was performed three times. After 
stepwise quality assessment, appropriate cases were selected 
for statistical analyses to detect differences in the lncRNA 
expression levels in tissue samples (Supplementary Figure 4).
Transfection, RNA isolation, and real-time PCR
Knockdown of MALAT1 was performed using 
three types of si-MALAT1 duplexes, si-MALAT1-a, -b, 
and -c (Bioneeroligosynthesis, Daejeon, South Korea), 
and a scramble negative control, si-NC (SN-1002, 
Bioneeroligosynthesis). The siRNAs were transfected 
using 4D-Nucleofector X unit (V4XC-1024, Lonza, Basel, 
Switzerland) and the Lonza 4D Nucleofector™system 
(Lonza) according to the manufacturer instructions. In 
brief, cells were grown in 6well plates and transfected 
with cocktails of the three si-MALAT1s (a, b, and c) 
at a concentration of 200pmol per well. After checking 
the transfection efficiency, each si-MALAT1 of a 
200pmol concentration was individually transfected to 
the cells. Sequences of si-MALAT1 are summarized in 
Supplementary Table 5. The cells were harvested after 
48h. Experiments were performed independently three 
or more times. After initial screening of the transfection 
efficiency in the T and NK cell lymphoma cell lines, the 
HH cell line was finally selected for further study.
RNA was isolated with RNeasy plus mini kit 
(Qiagen), and cDNA was reverse transcribed using a cDNA 
synthesis kit (Invitrogen, Carlsbad, CA, USA). The TaqMan 
probes were as follows: GAPDH (Hs99999905-m1, ABI; 
Life Technologies), MALAT1 (Hs00273907-s1, ABI). 
Quantitative PCR was performed using ABI StepOnePlus™ 
(Applied Biosystems) under the following conditions: 50°C 
for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15sec, and 
60°C for 1min. Relative expression levels of MALAT1were 
determined by the comparative method (2-ΔΔCt) against the 
reference gene GAPDH.
RNA immunoprecipitation assay
RNA immunoprecipitation was performed 
using Imprint® RNA Immunoprecipitation Kit (RIP, 
Sigma-Aldrich, St. Louis, MO, USA) according 
to the manufacturer protocols. From the RNA 
immunoprecipitation fraction, RNA was purified with 
TRI Reagent (T9424, Sigma-Aldrich), and then treated 
with DNase I (AMPD1, Sigma-Aldrich). cDNA was 
synthesized using the cDNA Synthesis Kit (Invitrogen), 
and fold enrichment of MALAT1 expression was finally 
determined through quantitative real-time PCR. MALAT1 
fold enrichment of the RNA immunoprecipitation fraction 
for each target antibody was normalized to the RNA 
immunoprecipitation fraction of the control antibody 
(IgG). The details of the antibodies used in this study are 
summarized in Supplementary Table 6.
Western blot analysis
The antibodies used are summarized in 
Supplementary Table 6. For visualization, the proteins 
were enhanced using Amersham ECL Plus Western 
Blotting Detection System (GE Healthcare Life Sciences, 
UK). The protein expression level was determined relative 
to the GAPDH level.
Statistical analysis
High or low expression of lncRNAs was determined 
using Youden’s index for survival. Pearson’s χ2 test or 
Fisher’s exact test was used to compare differences 
between variables, and the Spearman coefficient was used 
for correlation analysis. Overall survival curves were 
plotted using the Kaplan–Meier method and compared 
using the log-rank test. Multiple linear regression analysis 
was used for probing the interactions of markers. A 
P-value <0.05 was considered statistically significant. 
Statistical analyses were performed using IBM SPSS 22 
software for Windows (IBM Corp, Somers, NY, USA).
ACKNOWLEDGMENTS
This study was supported by the Basic Science 
Research Program through the National Research 
Foundation of Korea (NRF) funded by the Ministry 
of Education (NRF-2015R1D1A1A09059399) and 
the SMF scholarship fund from the Seegene Medical 
Foundation.
CONFLICTS OF INTEREST
The authors have no conflicts of interest to declare.
REFERENCES
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, 
Stein H, Thiele J, Vardiman JW. WHO Classification of 
Tumours of Haematopoietic and Lymphoid Tissues. Lyon, 
France: IARC Press; 2008.
Oncotarget31316www.impactjournals.com/oncotarget
2. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding 
RNAs: a new frontier in the study of human diseases. 
Cancer Lett. 2013; 339: 159-66. doi: 10.1016/j.
canlet.2013.06.013.
3. Kogo R, Shimamura T, Mimori K, Kawahara K, Imoto 
S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, 
Miyano S, Mori M. Long noncoding RNA HOTAIR 
regulates polycomb-dependent chromatin modification and 
is associated with poor prognosis in colorectal cancers. 
Cancer Res. 2011; 71: 6320-6. doi: 10.1158/0008-5472.
can-11-1021.
4. Chen FJ, Sun M, Li SQ, Wu QQ, Ji L, Liu ZL, Zhou 
GZ, Cao G, Jin L, Xie HW, Wang CM, Lv J, De W, et 
al. Upregulation of the long non-coding RNA HOTAIR 
promotes esophageal squamous cell carcinoma metastasis 
and poor prognosis. Mol Carcinog. 2013; 52: 908-15. doi: 
10.1002/mc.21944.
5. Cui L, Xie XY, Wang H, Chen XL, Liu SL, Hu LN. 
[Expression of long non-coding RNA HOTAIR mRNA in 
ovarian cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban. 
2013; 44: 57-9.
6. Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W. The long 
non-coding RNA HOTAIR indicates a poor prognosis and 
promotes metastasis in non-small cell lung cancer. BMC 
Cancer. 2013; 13: 464. doi: 10.1186/1471-2407-13-464.
7. Qiu MT, Hu JW, Yin R, Xu L. Long noncoding RNA: 
an emerging paradigm of cancer research. Tumour Biol. 
2013; 34: 613-20. doi: 10.1007/s13277-013-0658-6.
8. Sorensen KP, Thomassen M, Tan Q, Bak M, Cold S, 
Burton M, Larsen MJ, Kruse TA. Long non-coding 
RNA HOTAIR is an independent prognostic marker of 
metastasis in estrogen receptor-positive primary breast 
cancer. Breast Cancer Res Treat. 2013; 142: 529-36. doi: 
10.1007/s10549-013-2776-7.
9. Tang L, Zhang W, Su B, Yu B. Long noncoding RNA 
HOTAIR is associated with motility, invasion, and 
metastatic potential of metastatic melanoma. Biomed Res 
Int. 2013; 2013: 251098. doi: 10.1155/2013/251098.
10. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid 
O, Gordon MS, Sosman JA, McDermott DF, Powderly 
JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, et 
al. Predictive correlates of response to the anti-PD-L1 
antibody MPDL3280A in cancer patients. Nature. 2014; 
515: 563-7. doi: 10.1038/nature14011.
11. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb 
proteins in hematologic malignancies. Blood. 2010; 
116:5465-75. doi: 10.1182/blood-2010-05-267096.
12. Martin-Perez D, Sanchez E, Maestre L, Suela J, Vargiu 
P, Di Lisio L, Martinez N, Alves J, Piris MA, Sanchez-
Beato M. Deregulated expression of the polycomb-group 
protein SUZ12 target genes characterizes mantle cell 
lymphoma. Am J Pathol. 2010; 177: 930-42. doi: 10.2353/
ajpath.2010.090769.
13. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, 
Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer 
F, Yap D, Humphries RK, Griffith OL, et al. Somatic 
mutations altering EZH2 (Tyr641) in follicular and diffuse 
large B-cell lymphomas of germinal-center origin. Nat 
Genet. 2010; 42: 181-5. doi: 10.1038/ng.518.
14. Isin M, Ozgur E, Cetin G, Erten N, Aktan M, Gezer U, 
Dalay N. Investigation of circulating lncRNAs in B-cell 
neoplasms. Clin Chim Acta. 2014; 431c: 255-9. doi: 
10.1016/j.cca.2014.02.010.
15. Wang GG, Konze KD, Tao J. Polycomb genes, miRNA, 
and their deregulation in B-cell malignancies. Blood. 
2015; 125: 1217-25. doi: 10.1182/blood-2014-10-606822.
16. Wu L, Murat P, Matak-Vinkovic D, Murrell A, 
Balasubramanian S. Binding interactions between 
long noncoding RNA HOTAIR and PRC2 proteins. 
Biochemistry. 2013; 52: 9519-27. doi: 10.1021/bi401085h.
17. Yamamoto Y, Abe A, Emi N. Clarifying the impact of 
polycomb complex component disruption in human 
cancers. Mol Cancer Res. 2014; 12: 479-84. doi: 
10.1158/1541-7786.mcr-13-0596.
18. Rajasekhar VK, Begemann M. Concise review: roles of 
polycomb group proteins in development and disease: a 
stem cell perspective. Stem Cells. 2007; 25: 2498-510. 
doi: 10.1634/stemcells.2006-0608.
19. Wang W, Zhu Y, Li S, Chen X, Jiang G, Shen Z, Qiao 
Y, Wang L, Zheng P, Zhang Y. Long noncoding RNA 
MALAT1 promotes malignant development of esophageal 
squamous cell carcinoma by targeting beta-catenin via 
Ezh2. Oncotarget. 2016; 7:25668-82. doi: 10.18632/
oncotarget.8257.
20. Wu Y, Zhang L, Zhang L, Wang Y, Li H, Ren X, Wei F, 
Yu W, Liu T, Wang X, Zhou X, Yu J, Hao X. Long non-
coding RNA HOTAIR promotes tumor cell invasion and 
metastasis by recruiting EZH2 and repressing E-cadherin 
in oral squamous cell carcinoma. Int J Oncol. 2015; 46: 
2586-94. doi: 10.3892/ijo.2015.2976.
21. Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, 
Zhang J, Huang H. LncRNA MALAT1 enhances 
oncogenic activities of EZH2 in castration-resistant 
prostate cancer. Oncotarget. 2015; 6: 41045-55. doi: 
10.18632/oncotarget.5728.
22. Sanulli S, Justin N, Teissandier A, Ancelin K, Portoso M, 
Caron M, Michaud A, Lombard B, da Rocha ST, Offer J, 
Loew D, Servant N, Wassef M, et al. Jarid2 Methylation 
via the PRC2 Complex Regulates H3K27me3 Deposition 
during Cell Differentiation. Mol Cell. 2015; 57: 769-83. 
doi: 10.1016/j.molcel.2014.12.020.
23. Lu L, Luo F, Liu Y, Liu X, Shi L, Lu X, Liu Q. 
Posttranscriptional silencing of the lncRNA MALAT1 by 
miR-217 inhibits the epithelial-mesenchymal transition 
via enhancer of zeste homolog 2 in the malignant 
transformation of HBE cells induced by cigarette smoke 
extract. Toxicol Appl Pharmacol. 2015; 289: 276-85. doi: 
10.1016/j.taap.2015.09.016.
24. Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, 
Tabatabai ZL, Ishii N, Dahiya R. Long Noncoding RNA 
Oncotarget31317www.impactjournals.com/oncotarget
MALAT1 Promotes Aggressive Renal Cell Carcinoma 
through Ezh2 and Interacts with miR-205. Cancer Res. 
2015; 75: 1322-31. doi: 10.1158/0008-5472.can-14-2931.
25. Kim SH, Yang WI, Min YH, Ko YH, Yoon SO. The role 
of the polycomb repressive complex pathway in T and NK 
cell lymphoma: biological and prognostic implications. 
Tumour Biol. 2016; 37: 2037-47. doi: 10.1007/
s13277-015-3977-y.
26. Fang Y, Fullwood MJ. Roles, Functions, and Mechanisms 
of Long Non-coding RNAs in Cancer. Genomics 
Proteomics Bioinformatics. 2016; 14: 42-54. doi: 
10.1016/j.gpb.2015.09.006.
27. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider 
PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, 
Berdel WE, Serve H, et al. MALAT-1, a novel noncoding 
RNA, and thymosin beta4 predict metastasis and survival 
in early-stage non-small cell lung cancer. Oncogene. 2003; 
22: 8031-41. doi: 10.1038/sj.onc.1206928.
28. Tian X, Xu G. Clinical value of lncRNA MALAT1 as a 
prognostic marker in human cancer: systematic review 
and meta-analysis. BMJ Open. 2015; 5: e008653. doi: 
10.1136/bmjopen-2015-008653.
29. Wei Y, Niu B. Role of MALAT1 as a Prognostic Factor for 
Survival in Various Cancers: A Systematic Review of the 
Literature with Meta-Analysis. Dis Markers. 2015; 2015: 
164635. doi: 10.1155/2015/164635.
30. Xiao H, Tang K, Liu P, Chen K, Hu J, Zeng J, Xiao W, 
Yu G, Yao W, Zhou H, Li H, Pan Y, Li A, et al. LncRNA 
MALAT1 functions as a competing endogenous RNA to 
regulate ZEB2 expression by sponging miR-200s in clear 
cell kidney carcinoma. Oncotarget. 2015; 6: 38005-15. 
doi: 10.18632/oncotarget.5357.
31. Zhai H, Li XM, Maimaiti A, Chen QJ, Liao W, Lai HM, 
Liu F, Yang YN. Prognostic value of long noncoding RNA 
MALAT1 in digestive system malignancies. Int J Clin Exp 
Med. 2015; 8: 18099-106.
32. Wang J, Pan Y, Wu J, Zhang C, Huang Y, Zhao R, Cheng 
G, Liu J, Qin C, Shao P, Hua L, Wang Z. The Association 
between Abnormal Long Noncoding RNA MALAT-1 
Expression and Cancer Lymph Node Metastasis: A Meta-
Analysis. Biomed Res Int. 2016; 2016: 1823482. doi: 
10.1155/2016/1823482.
33. Guo F, Guo L, Li Y, Zhou Q, Li Z. MALAT1 is an 
oncogenic long non-coding RNA associated with tumor 
invasion in non-small cell lung cancer regulated by DNA 
methylation. Int J Clin Exp Pathol. 2015; 8: 15903-10.
34. Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang S, Liu X. 
Long noncoding RNA MALAT1 as a potential therapeutic 
target in osteosarcoma. J Orthop Res. 2015. doi: 10.1002/
jor.23105.
35. Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. 
MALAT1 promotes the proliferation and metastasis 
of osteosarcoma cells by activating the PI3K/Akt 
pathway. Tumour Biol. 2015; 36: 1477-86. doi: 10.1007/
s13277-014-2631-4.
36. Fang D, Yang H, Lin J, Teng Y, Jiang Y, Chen J, Li Y. 
17beta-estradiol regulates cell proliferation, colony 
formation, migration, invasion and promotes apoptosis 
by upregulating miR-9 and thus degrades MALAT-1 
in osteosarcoma cell MG-63 in an estrogen receptor-
independent manner. Biochem Biophys Res Commun. 
2015; 457: 500-6. doi: 10.1016/j.bbrc.2014.12.114.
37. Shi XS, Li J, Yang RH, Zhao GR, Zhou HP, Zeng WX, 
Zhou M. Correlation of increased MALAT1 expression 
with pathological features and prognosis in cancer 
patients: a meta-analysis. Genet Mol Res. 2015; 14: 
18808-19. doi: 10.4238/2015.December.28.30.
38. Yan J, Zhou X, Dang Y, Yin C, Zhang G. Prognostic role 
of the long non-coding RNA metastasis-associated lung 
adenocarcinoma transcript 1 in various cancers: A meta-
analysis. Mol Clin Oncol. 2016; 4: 100-6. doi: 10.3892/
mco.2015.657.
39. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y. 
TGF-beta-induced upregulation of malat1 promotes 
bladder cancer metastasis by associating with suz12. Clin 
Cancer Res. 2014; 20: 1531-41. doi: 10.1158/1078-0432.
ccr-13-1455.
40. Vogel UF, Bueltmann BD. Simple, inexpensive, and 
precise paraffin tissue microarrays constructed with a 
conventional microcompound table and a drill grinder. 
Am J Clin Pathol. 2006; 126: 342-8. doi: 10.1309/
f2q38dxn1v1v4gqm.
